Quantitative proton-decoupled
            <sup>31</sup>
            P MRS and
            <sup>1</sup>
            H MRS in the evaluation of Huntington's and Parkinson's diseases

Hoang, Tuan; Blüml, Stefan; Dubowitz, David J.; Moats, Rex; Kopyov, Oleg; Jacques, David; Ross, Brian D.

doi:10.1212/wnl.50.4.1033

Cited by 139 publications

(106 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The CrϩPCr signal thus reflects the state of systemic energy use and storage (Stockler et al 1996;Valenzuela and Sachdev 2001). The reduction in CrϩPCr is, in effect, considered to be associated with cellular energy impairment (Hoang et al 1998;SanchezPernaute et al 1999).…”

Section: Discussionmentioning

confidence: 99%

Metabolite Alterations in Basal Ganglia Associated with Methamphetamine-related Psychiatric Symptoms A Proton MRS Study

Sekine

Minabe

Kawai

et al. 2002

Neuropsychopharmacology

View full text Add to dashboard Cite

Following the chronic use of methamphetamine, some individuals experience psychosis and anxiety. One reason may be the persistence of metabolite abnormalities in the brain of currently abstinent former methamphetamine users.In this study, N-acetylaspartate (NAA), creatine plus phosphocreatine (Cr ϩ PCr), and choline-containing compound (Cho) levels were measured in the left and right basal ganglia using proton magnetic resonance spectroscopy (MRS) The number of abusers of the highly addictive drug methamphetamine has risen substantially worldwide and this has raised important concerns (Woolverton et al. 1984;Baberg et al. 1996;Shaw 1999). For example, chronic methamphetamine users show psychosis and anxiety following intoxication and withdrawal (Seivewright 2000). In addition, in some individuals, these psychiatric states may be present for months or even years after cessation of methamphetamine use (Sato et al. 1992;Iwanami et al. 1994;Buffenstein et al. 1999;Iyo et al. 1999). Although there are growing clinical observations on the neurotoxicology of chronic methamphetamine use, the mechanism by which the residual psychiatric problems arise from chronic methamphetamine NO . 3 use remains unknown. In rodents and baboons, methamphetamine has been shown to be toxic to dopaminergic and serotonergic neurons (Nakayama et al. 1993;Villemagne et al. 1998;Kokoshka et al. 1998). These neurotoxic effects include decreased concentrations of dopamine and serotonin in the brain and a reduction of dopamine and serotonin transporters, as well as loss of ATP and mitochondrial dysfunction in dopaminergic neurons (Chan et al. 1994;Burrows et al. 2000;Lotharius and O'Malley 2001). Human positron emission tomography (PET) studies have reported a significant reduction of dopamine transporter density in methamphetamine users Volkow et al. 2001), and that the reduction observed in methamphetamine users is associated with psychomotor impairment (Volkow et al. 2001). Recently, we have also found that the dopamine transporter density in methamphetamine users is inversely related to the length of methamphetamine use and the magnitude of psychiatric symptoms, including psychotic symptoms (Sekine et al. 2001).In vivo proton magnetic resonance spectroscopy ( 1 H MRS) and its variant 1 H MRS techniques provide insight into the metabolism of several endogenous brain chemicals (Miller 1991;Jackson 1992). A recent 1 H MRS study showed evidence for long-term metabolite alterations in currently abstinent former methamphetamine users, that is, reduced concentration of both N-acetylaspartate (NAA) and creatine plus phosphocreatine (Cr ϩ PCr) in the right basal ganglia (Ernst et al. 2000). However, it is unclear whether these abnormalities detected by 1 H MRS are related to psychiatric symptoms that are frequently observed in abstinent methamphetamine users.In this study, we investigated changes of the chemistry in the basal ganglia of abstinent methamphetamine users by 1 H MRS, and examined any relationship between the changes and clinical cha...

show abstract

Section: Discussionmentioning

confidence: 99%

Metabolite Alterations in Basal Ganglia Associated with Methamphetamine-related Psychiatric Symptoms A Proton MRS Study

Sekine

Minabe

Kawai

et al. 2002

Neuropsychopharmacology

View full text Add to dashboard Cite

show abstract

“…Furthermore, when patients were grouped based on clinical criteria, neural networks could be trained to classify spectra into these groups and controls to a relatively high degree. Published 1 H MRS results suggest that there are generally no dramatic differences in metabolite concentrations between PD patients and controls (5)(6)(7)(8)23,24). Furthermore, where differences do exist, they are frequently not sufficient to enable classification of individuals from a data set of patients and controls.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, where differences do exist, they are frequently not sufficient to enable classification of individuals from a data set of patients and controls. For instance, Hoang, et al (5) concluded that while small, systematic abnormalities in NAA (decreased), Cr (decreased), and Cho-containing compounds (increased) were evident, they were insufficient to make diagnosis possible in an individual patient. Davie, et al (6) found that only one of nine patients exhibited a markedly reduced NAA/Cr ratio compared with a control group.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Applications of neural network analyses to in vivo ¹H magnetic resonance spectroscopy of Parkinson disease patients

Axelson¹,

Bakken²,

Gribbestad³

et al. 2002

Magnetic Resonance Imaging

View full text Add to dashboard Cite

Purpose: To apply neural network analyses to in vivo magnetic resonance spectra of controls and Parkinson disease (PD) patients for the purpose of classification. Materials and Methods:Ninety-seven in vivo proton magnetic resonance spectra of the basal ganglia were recorded from 31 patients with (PD) and 14 age-matched healthy volunteers on a 1.5-T imager. The PD patients were grouped as follows: probable PD (N ϭ 15), possible PD (N ϭ 11), and atypical PD (N ϭ 5). Total acquisition times of approximately five minutes were achieved with a TE (echo time) of 135 msec, a TR (repetition time) of 2000 msec, and 128 scan averages. Neural network (back propagation, Kohonen, probabilistic, and radial basis function) and related (generative topographic mapping) data analyses were performed.Results: Conventional data analysis showed no statistically significant differences in metabolite ratios based on measuring signal intensities. The trained networks could distinguish control from PD with considerable accuracy (true positive fraction 0.971, true negative fraction 0.933). When four classes were defined, approximately 88% of the predictions were correct. The multivariate analysis indicated metabolic changes in the basal ganglia in PD. Conclusion:A variety of neural network and related approaches can be successfully applied to both qualitative visualization and classification of in vivo spectra of PD patients.

show abstract

“…104 Animals have a quantifiable motor deficit, but the characteristic Lewy bodies observed in human patients are not seen, and there is nonspecific toxin-induced damage to neighboring neurons. This model has been particularly useful for pharmacological screening but does not replicate many key 75 Tkac et al, 148 Pfeuffer et al, 74 Govindaraju et al 73 Spinocerebellar ataxia Huntington's disease Characterization of the metabolite perturbations and impaired energy metabolism in PD Hoang et al, 79 Jenkins et al 28,81 Metabolic characterization of toxin-induced and transgenic animal models of HD Tsang et al, 76 Jenkins et al, 121 van Dellen et al, 120 Dautry et al 113,149 Evaluation of creatine supplementation in HD models and patients…”

Section: Preclinical Metabonomic Studiesmentioning

confidence: 99%

The application of NMR-based metabonomics in neurological disorders

Holmes

Tsang

Tabrizi

2006

NeuroRX

View full text Add to dashboard Cite

Summary: Advances in postgenomic technologies have radically changed the information output from complex biological systems, generating vast amounts of high complexity data that can be interpreted by means of chemometric and bioinformatic methods to achieve disease diagnosis and prognosis. Highresolution nuclear magnetic resonance (NMR) spectroscopy of biofluids such as plasma, cerebrospinal fluid (CSF), and urine can generate robust, interpretable metabolic fingerprints that contain latent information relating to physiological or pathological status. This technology has been successfully applied to both preclinical and clinical studies of neurodegenerative diseases such as Huntington's disease, muscular dystrophy, and cerebellar ataxia. An extension of this technology, 1 H magicangle-spinning (HRMAS) NMR spectroscopy, can be used to generate metabolic information on small intact tissue samples, providing a metabolic link between metabolic profiling of biofluids and histology. In this review we provide a summary of high-resolution NMR studies in neurodegenerative disease and explore the potential of metabonomics in evaluating disease progression with respect to therapeutic intervention.

show abstract

Quantitative proton-decoupled ³¹ P MRS and ¹ H MRS in the evaluation of Huntington's and Parkinson's diseases

Abstract: Previously described failure of global energy metabolism in HD was not confirmed. However, quantitative 1-hydrogen MRS and decoupled 31-phosphorus MRS are sensitive to +/-10% alterations in key cerebral metabolites, and may be of value in noninvasive monitoring of appropriate therapies.

Cited by 139 publications

References 14 publications

Metabolite Alterations in Basal Ganglia Associated with Methamphetamine-related Psychiatric Symptoms A Proton MRS Study

Metabolite Alterations in Basal Ganglia Associated with Methamphetamine-related Psychiatric Symptoms A Proton MRS Study

Applications of neural network analyses to in vivo ¹H magnetic resonance spectroscopy of Parkinson disease patients

The application of NMR-based metabonomics in neurological disorders

Contact Info

Product

Resources

About

Quantitative proton-decoupled 31 P MRS and 1 H MRS in the evaluation of Huntington's and Parkinson's diseases

Abstract: Previously described failure of global energy metabolism in HD was not confirmed. However, quantitative 1-hydrogen MRS and decoupled 31-phosphorus MRS are sensitive to +/-10% alterations in key cerebral metabolites, and may be of value in noninvasive monitoring of appropriate therapies.

Cited by 139 publications

References 14 publications

Metabolite Alterations in Basal Ganglia Associated with Methamphetamine-related Psychiatric Symptoms A Proton MRS Study

Metabolite Alterations in Basal Ganglia Associated with Methamphetamine-related Psychiatric Symptoms A Proton MRS Study

Applications of neural network analyses to in vivo 1H magnetic resonance spectroscopy of Parkinson disease patients

The application of NMR-based metabonomics in neurological disorders

Contact Info

Product

Resources

About

Quantitative proton-decoupled ³¹ P MRS and ¹ H MRS in the evaluation of Huntington's and Parkinson's diseases

Applications of neural network analyses to in vivo ¹H magnetic resonance spectroscopy of Parkinson disease patients